These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2588515)

  • 1. [Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
    Korkushko OV; Bogatskaia LN; Kovalenko AN; Novikova SN; Kotko DN
    Vrach Delo; 1989 Aug; (8):19-22. PubMed ID: 2588515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 5. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of adebit on carbohydrate and insulin metabolism in childhood obesity].
    Blatniczky L; Kautzky L; Péter F
    Orv Hetil; 1986 Jun; 127(23):1381-4, 1387-8. PubMed ID: 3523380
    [No Abstract]   [Full Text] [Related]  

  • 9. [Vitamin B 12 absorption disorders in diabetic patients treated with adebit].
    Keszthelyi B; Tóth A; Novotny S; Fónay K; Jávor T; Past T; Bero T
    Orv Hetil; 1976 Apr; 117(16):963-4. PubMed ID: 1272562
    [No Abstract]   [Full Text] [Related]  

  • 10. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial.
    Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A
    Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of polyenylphosphatidylcholine (PPC) on serum lipids in patients with hyperlipoproteinemia. A double-blind study].
    Horsch AK; Majolk I; Heuck CC; Göpfert E
    Vasa; 1986; 15(3):251-5. PubMed ID: 3532609
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum lipoprotein pattern after SAMe-treatment.
    Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
    Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S; La Spina E; Fichera C; Cultrera E; Patanè M; Ciulla P
    Arch Sci Med (Torino); 1982; 139(4):441-8. PubMed ID: 7168636
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lipid metabolism disorders and soft palate lipid changes in myocardial infarct].
    Dubejko J; Markiewicz M; Michałowski R; Kutarski A
    Pol Tyg Lek; 1980 Aug; 35(32):1217-9. PubMed ID: 7433204
    [No Abstract]   [Full Text] [Related]  

  • 16. [Blood plasma prostaglandins and their role in disorders of lipid metabolism in ischemic heart disease caused by coronary arteriosclerosis].
    Bochkareva EV; Zykova VP; Lobova NM; Polesskiĭ VA; Gadzhanova SI
    Ter Arkh; 1980; 52(5):18-22. PubMed ID: 7404361
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical use of a new hypoglycemic agent: buformin].
    Leone S; Modicano V; Scapellato L
    Clin Ter; 1976 Sep; 78(6):527-35. PubMed ID: 1017159
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A; Ljachnicky N
    Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 20. [Essentiale in the treatment of hypertension in patients in the older age groups].
    Ena LM; Negaré AI
    Vrach Delo; 1989 Oct; (10):77-80. PubMed ID: 2617993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.